This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Botox - Next Generation

Allergan plc

Drug Names(s): Targeted Botox

Description: BioMedTracker has separate profiles for the therapeutic and cosmetic versions of Botox.

Targeted Botox or Next Generation Botox is a re-engineered botulinum toxin type A containing a modified binding site to selectively target sensory pain nerves and not the adjacent muscles.

Botox is Botulinum Toxin Type A. The toxin reduces muscle contractions by entering nerve terminals at their junctions with muscles (neuromuscular junction) and inhibiting the release of the neurotransmitter acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings. Botox may have other mechanisms, as well, such as inhibiting the release of chemicals that mediate the sensation of pain.

Deal Structure: All historical revenue for different versions of Botox is recorded under Botox - Therapeutic.

Actavis and Allergan
In November 2014, Actavis and Allergan announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of Actavis shares on November 14, 2014, the transaction is valued at approximately $66 billion, or $219 per Allergan share.

In March 2015, Actavis announced that it has completed the acquisition of Allergan in a cash and equity transaction valued at approximately $70.5 billion.

In June 2015, Actavis announced that the company has adopted Allergan as its new global name and will begin trading under a new symbol (AGN). The company name change follows the acquisition of Allergan in March 2015 and the...See full deal structure in Biomedtracker


Botox - Next Generation News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug